Bullzeye FinancialAurobindo Pharma Ltd.
NSE: AUROPHARMA · Healthcare
Declining volume during an uptrend near 52-week highs, absent earnings visibility, and modest Q2 growth (6% YoY) suggest the 56% rally…
FDA approval for Beclomethasone HFA inhalation aerosol is confirmed and expands the US respiratory generics portfolio; technical structure remains bullish (EMA 20 > 50 > 200, RSI 57.72) with 64.89 percentage points of outperformance versus NIFTY over 12 months.
Volume has collapsed to 57% of 20-day average despite the confirmed catalyst, and Q2 FY26 showed only 6% YoY revenue growth—insufficient to justify a 56% stock rally without earnings visibility or valuation data.
Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.
-
Bearish 28 Sep 2026 → now Scores 28 Oct 2026₹1,697.50 → ₹1,697.50 0.0%
Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.
How we score →